TABLE 1.
Characteristics and drug susceptibilities of selected viruses
| Selecting drug | Time point (day) | Concn (FC over EC50) | Selected virus |
|||||
|---|---|---|---|---|---|---|---|---|
| Amino acid substitution(s) | Susceptibility (FC from wild-type control [HIV-1IIIB])a |
|||||||
| TAF | TFV | FTC | EFV | EVG | ||||
| TAF | 148 | 224 nM (16×) | K65R | 6.5b | 5.5b | 8.5b | 1.4 | 1.7 |
| TFV | 154 | 56 μM (16×) | K65R S68(S/N/R/K) | 6.5b | 5.1b | 6.7b | 1.5 | 1.4 |
a
EC50 against HIV-1IIIB in MT-2 standard assay was 10 nM, 2.9 μM, 1.2 nM, 0.77 μM, 0.26 μM, and 1.5 nM for TAF, TFV, EVG, FTC, ZDV, and EFV respectively. TAF, tenofovir alafenamide; TFV, tenofovir; FTC, emtricitabine; AZT, zidovudine; EFV, efavirenz; EVG, elvitegravir. Fold changes of the average EC50 were obtained from 5 independent experiments.
b
P < 0.05 (t test).